An early clinical trial has revealed promising results for patients with advanced lung cancer. One-third of the participants experienced a reduction in tumor size, a significant finding that is leading to larger ongoing trials.
The trial specifically targeted individuals with advanced non-small-cell lung cancer who had previously undergone standard treatments, such as chemotherapy. The results were published in the New England Journal of Medicine.
The trial highlights a pancreatic cancer drug that has shown effectiveness against non-small-cell lung cancer, the most prevalent form of the disease. This information was gathered and reported by Pascal Pochard-Casabianca, with images via AFP, and was made public on September 2, 2026, at 5:17 PM EDT.
Increased Funding Needed for Psychiatric Hospitals 
Trump Administration Distributes ACA Refund Checks 
Higher Consumption of Ultra-Processed Foods Linked to Increased Health Risks 
Understanding Inflammation: Myths and Facts 
Calm Parenting: Strategies to Manage Stress 
Trump’s Executive Order to Combat Mosquitoes and Ticks in D.C.